SEQ ID NO: 1 Peptide for RA Bone Erosion and Synoviocyte Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatoid arthritis, such as Humira and Xeljanz, have safety concerns and do not effectively prevent bone erosion and synovial hyperplasia, leading to joint destruction and disability.
Innovation Solution
A peptide with the amino acid sequence of SEQ ID NO: 1 is used to inhibit the proliferation and migration of synoviocytes, thereby preventing bone resorption and maintaining bone integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional DMARD therapies (Humira, Xeljanz) are used to treat rheumatoid arthritis, then inflammation and immune response are suppressed, but bone erosion and synovial hyperplasia are not effectively prevented, leading to joint destruction
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of FLS-mediated bone erosion by focusing on the FLS-RANKL-osteoclast axis. Instead of broad immunosuppression, the invention specifically interrupts the bone erosion pathway by inhibiting FLS proliferation and RANKL expression, thereby preventing osteoclast differentiation and bone resorption while avoiding off-target effects on other immune functions.
Solution Approach 2:
The patent employs small molecule compounds that bind to and modulate the activity of FLS-specific targets (such as RANKL or its receptor RANK). By changing the molecular interaction parameters between FLS and osteoclasts, the invention achieves selective inhibition of bone erosion pathways without broadly suppressing the immune system, thereby improving bone protection while maintaining immune surveillance.
2Reliability
If FLS proliferation and migration are not inhibited, then synovial hyperplasia progresses, but current therapies fail to target this key factor, resulting in continued joint destruction
Solution Approach 1:
The patent extracts FLS as the specific therapeutic target, recognizing these cells as the primary drivers of synovial hyperplasia and joint destruction. By developing compounds that selectively inhibit FLS proliferation and migration through targeted molecular mechanisms (such as blocking FLS-RANKL interactions or inhibiting FLS-specific signaling pathways), the invention directly addresses the root cause of synovial hyperplasia without affecting other synovial cell types.
3Reliability
If bone resorption is not inhibited, then osteoclast activity dominates over bone formation, but existing therapies do not sufficiently address this imbalance, leading to subchondral bone destruction
Solution Approach 1:
The patent applies preliminary action by inhibiting FLS proliferation and RANKL expression before osteoclasts can be fully activated and cause significant bone erosion. By targeting the upstream FLS cells that drive osteoclast differentiation, the invention prevents the formation of excessive osteoclasts before they can resorb bone, thereby achieving bone protection at an earlier stage in the pathological cascade.
Solution Approach 2:
The patent modifies the molecular parameters of the FLS-osteoclast interaction by introducing small molecule compounds that bind to key proteins in this axis (such as RANKL or RANK). These compounds change the binding affinity and signaling intensity, thereby reducing osteoclast differentiation and bone resorption activity while maintaining physiological bone turnover.
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
Provided is a peptide for use in skeleton protection, comprising the amino acid sequence of SEQ ID NO: 1. The present invention proves that administering the peptide of SEQ ID NO: 1 can ameliorate cortical bone erosion of calcaneus bone resulting from rheumatoid arthritis (RA) and restore the decline of RA-induced bone mineral density. Therefore, the peptide of SEQ ID NO: 1 possesses a therapeutic effect for skeleton protection.